Clinical Trial Update: Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial [NA]

View source ↗

Summary

A Phase III non-CTIMP trial evaluating the Magnetic Resonance Tumour Regression Grade (mrTRG) as a novel biomarker in rectal cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Snippet

Sponsor: Imperial College London | Conditions: Rectal Cancer | NA | Status: RECRUITING